Switzerland· 62341002
Caprelsa
A vandetanib product containing vandetanibum, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Vandetanib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01EX04 (vandetanib), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 8 of them publish a price we can compare per daily dose
Vandetanib · ATC L01EX04
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of vandetanib costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), so markets compare like for like.
- Switzerland: $239.02 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Vandetanib · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- CH Switzerland$239.02
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Active substance
- vandetanibum
- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- L01EX04
- ATC class
- Vandetanib
- Defined daily dose
- 0.3 g, O
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680623410023Blist 30 StkCHF 4907.65
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
351 interactions on record for vandetanib.
Graded by severity as the source publishes them — 244 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Vandetanib · interactions on record
351 records
- 244 severe
- 95 moderate
- 12 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Vandetanib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaCAPRELSASANOFI-AVENTIS CANADA INC
- United KingdomCaprelsa 300mg tabletsSanofi
- FinlandCaprelsaEsteve Pharmaceuticals S.A.S.
- NorwayCaprelsaEsteve Pharmaceuticals S.A
- CzechiaCAPRELSAEsteve Pharmaceuticals S.A., Barcelona
- SpainCAPRELSA 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULAEsteve Pharmaceuticals S.A.
- FranceCAPRELSA 100 mg, comprimé pelliculéESTEVE PHARMACEUTICALS (ESPAGNE)
- IrelandCaprelsa 100 mg film-coated tabletsEsteve Pharmaceuticals S.A.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Caprelsa
- Liechtenstein · Caprelsa
- Norway · Caprelsa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/da0517bd-4453-4a5b-ada0-5ce204b3c594 GET /v1/drugs/da0517bd-4453-4a5b-ada0-5ce204b3c594?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "vandetanibum 300 mg",
"valid_from": "2022-08-01",
"limitations": "[{\"description\":\"Zur Behandlung von Patienten mit aggressivem und symptomatischem medullärem Schilddrüsenkarzinom (MTC) mit RET-Mutation (RET: Rearranged during transfection) bei Erwachsenen mit nicht resezierbarer, lokal fortgeschrittener oder metastasierter Erkrankung. Die Patienten sollen bis zur Progression der Erkrankung behandelt werden. Die Behandlung bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2023-05-01\",\"validTo\":null}]",
"galenic_form": "Tabl 300 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2012-12-01",
"self_retention_pct": 10
}See everything about vandetanib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.